ECE2015 Oral Communications Reproduction (5 abstracts)
Lipid accumulation product as a surrogate marker of metabolic syndrome in different phenotypes of polycystic ovary syndrome
Djuro Macut 1 , Ivana Bozic Antic 1 , Jelica Bjekic-Macut 2 , Danijela Vojnovic Milutinovic 3 , Dusan Ilic 1 , Bojana Popovic 1 , Tamara Bogavac 1 , Biljana Kastratovic-Kotlica 4 , Olivera Stanojlovic 5 , Tatjana Isailovic 1 , Valentina Elezovic 1 , Sanja Ognjanovic 1 , Milan Petakov 1 & Svetozar Damjanovic 1
1Clinic of Endocrinology, Diabetes and Metabolic Diseases and Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 2CHC Bezanijska kosa, Belgrade, Serbia; 3IBISS, University of Belgrade, Belgrade, Serbia; 4Clinic of Gynecology and Obstetrics, and Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 5Institute of Physiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Introduction: Lipid accumulation product (LAP) has been validated as good surrogate marker for the presence of metabolic syndrome (MetS) in general population. The aim of this study was to evaluate LAP in different PCOS phenotypes and to determine its association with MetS.
Methods: We evaluated 365 PCOS women (PCOS: 25.05±6.24−kg/m2; 25.48±5.21 years) diagnosed using ESHRE/ASRM criteria and 125 BMI-matched healthy women (controls: 25.41±5.16 kg/m2; 30.35±5.62 years). PCOS group was divided into four phenotypes: a (anovulation (ANOV), hyperandrogenism (HA), polycystic ovary morphology (PCOM)), B (ANOV, HA), C (HA, PCOM) and D (ANOV, PCOM). MetS was defined according to NCEP ATP III definition. LAP was calculated using formula ((WC-58)×triglycerides). ROC curve analysis was performed to determine associations of LAP and MetS.
Results: The prevalence of MetS in phenotypes/controls was as following: A: 20.8%, B: 27.5%, C: 17.5%, D: 5.3%, and in Controls: 6.4%. Phenotype D and Controls had lower (P<0.05) MetS prevalence than all other PCOS phenotypes. LAP was significantly lower (P<0.05) in phenotype D (19.11±25.51) and Controls (25.33±23.17) than in all other phenotypes (A: 35.37±41.29, B: 48.74±47.70, C: 32.55±38.11). ROC curve analysis indentified LAP cut off value of 25.94 to be the most preferable for predicting MetS in PCOS by NCEP ATP III criteria (AUC=0.95±0.01 (95% CI 0.93–0.97), sensitivity: 98.5%, specificity: 76.1%). This cut off value had higher negative than positive predictive value for the whole PCOS group (99.5% vs 52%, respectively) and also for the phenotypes (A: 100% vs 54%; B: 100% vs 58%; C: 98% vs 48%; D: 100% vs 33%).
Conclusion: Lipid accumulation product represent a strong and simple surrogate marker for the diagnosing of MetS in all susceptible women with PCOS, and regarding their clinical phenotypes as well.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more